BioNTech SE BNTX
Annual
Quarterly
No annual revenue total was found in BioNTech SE's SEC filings.
BioNTech SE (BNTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
251.20M
+4.7% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Germany
- Headquarters
- Mainz, Germany
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1776985
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 26, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 26, 2026 |
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
All 589 BioNTech SE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.